Why Is ELANCO ANIMAL HEALTH (ELAN) Stock Down Today?

ELANCO Animal Health shares fell 5.32% to $22.24 on Tuesday. The primary driver was a downgrade from Jefferies, which cut its rating to Hold and lowered its price target to $24. The firm cited pricing risks in the animal health sector, preferring IDEXX over Elanco and Zoetis.

What Happened

Jefferies downgraded Elanco Animal Health stock to Hold from Buy, citing concerns over pricing risks. The analyst firm also lowered its price target to $24. In a related move, Jefferies downgraded Zoetis on similar pricing concerns, while expressing a preference for IDEXX. This action followed a recent initiation of coverage by Goldman Sachs, which assigned a Buy rating and a $32 price target to the stock.

What The Data Shows

The stock opened at $23.00, a 2.1% gap down from the prior close of $23.49. It reached a session high of $23.47 at 9:30 AM ET before sliding to a low of $22.12 at 10:00 AM ET. Volume stood at 1.2 million shares, which is 0.2x the three-month daily average. Elanco has a market capitalization of $11.8 billion and is currently unprofitable, with trailing twelve months earnings per share of $0.41 and a net margin of 4.0%. Revenue grew 12.0% over the trailing twelve months. The stock has a beta of 1.71 and trades within a 52-week range of $19.40 to $27.98. Over the last eight sessions, the stock had risen 4.2% from $22.54 to $23.49. Recent insider activity includes five buys totaling $1.5 million and one sale of $100,000 in the last 90 days. A congressional sale of $1,001 to $15,000 was disclosed on August 4, 2026.

What To Watch

Investors will monitor how the market digests the Jefferies downgrade relative to the recent Goldman Sachs initiation. The stock’s recent trend, which saw it print two fresh 52-week highs and ten fresh 52-week lows on October 20, 2026, provides context for its current valuation.